October 2016

Report: Nine evidence-based approaches to transform drug development and commercialization

Monday, October 31, 2016

Life sciences companies increasingly are seeking new models to connect expanding sets of disparate, non-identified patient-level data streams to better develop and commercialize next-generation medicines. The need for practical, evidence-based approaches is especially acute at a time when scientific advances, the growing need for new medicines, and constrained budgets for healthcare and other social services are colliding.

[Read More]

Ebola-affected countries receive NIH support research training support

Monday, October 31, 2016

The recent Ebola epidemic in West Africa highlighted the need for better global preparedness and response to disease outbreaks. To help address that need in Guinea, Liberia and Sierra Leone—the countries most affected by the epidemic—the NIH has established a new program to strengthen the research capacity to study Ebola, Lassa fever, yellow fever and other emerging viral diseases. In the initiative’s first funding round, NIH’s Fogarty International Center is awarding grants to four U.S. institutions that will partner with West African academic centers to design training programs for their scientists and health researchers.

[Read More]

ICON, TriNetX partner

Monday, October 31, 2016

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has further improved its feasibility, protocol optimization and patient recruitment capabilities through the use of TriNetX.

[Read More]

Q2 Solutions, Illumina collaborate, enhance companion diagnostics capabilities

Monday, October 31, 2016

Q2 Solutions, a global clinical trials laboratory services organization, has announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q2 Solutions—EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays. The expansion of Q2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

[Read More]

How to develop efficiency in the study start-up process

Monday, October 31, 2016

The Pulse on Site Success by Christophe Berthoux

There are a number of perspectives related to the clinical research study start-up phase and how sites can best manage issues during this critical time frame. A number of elements are involved to efficiently achieve study start-up; however, these moving parts increase the likelihood of an opportunity for delay. Many experienced research sites aim to shorten timelines by taking advantage of the lag time that occurs between receipt of the contract and awaiting finalization for actual start-up. Streamlining the study start-up phase will not only facilitate smooth management from an internal standpoint, but it also may strengthen the relationship the site has with the sponsor or CRO, thus positioning the site well for the potential to gain more opportunities in the future.

[Read More]

Three Questions: Greg Sweatt, ePatientFinder

Monday, October 31, 2016

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with Greg Sweatt, co-founder and senior vice president of life sciences for ePatientFinder, a service that CROs and sponsors contract with to help those doctors close to sites mine their patient base for clinical trial subjects.

[Read More]